Person: BAYOĞLU, İBRAHİM VEDAT
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
BAYOĞLU
First Name
İBRAHİM VEDAT
Name
7 results
Search Results
Now showing 1 - 7 of 7
Publication Open Access PNI as a potential add-on biomarker to improve the IMDC intermediate prognostic score(2023-10-01) BAYOĞLU, İBRAHİM VEDAT; SEVER, NADİYE; YAŞAR, ALPER; ARIKAN, RUKİYE; SARI, MURAT; KÖSTEK, OSMAN; BAYOĞLU İ. V., Hüseynov J., Topal A., Sever N., Majidova N., Çelebi A., Yaşar A., ARIKAN R., Işık S., Hacıoğlu M. B., et al.Introduction: This study aimed to assess the role of the adjusted PNI-IMDC risk scoring system in stratifying the intermediate group of metastatic RCC patients who received TKIS in the first-line setting. Methods: A total of 185 patients were included. The adjusted PNI and IMDC model was used to divide the intermediate group into two groups: intermediate PNI-high and intermediate PNI-low groups. The statistical data were analyzed using Kaplan–Meier and Cox regression analysis. Results: The results showed that the adjusted PNI-IMDC risk score, classic IMDC, and PNI had similar prognostic values. Adjusted PNI-IMDC risk score might be used for a more homogeneous differentiation of the classic intermediate group. On the other hand, multivariate analysis revealed that the presence of nephrectomy, adjusted favorable/intermediate (PNI-high) group, ECOG performance score, and presence of bone metastasis were independent predictors of OS. Conclusions: Pre-treatment PNI, as a valuable and potential add-on biomarker to the adjusted PNI-IMDC classification model, can be helpful for establishing an improved prognostic model for intermediate group mRCC patients treated with first-line TKISs. Further validation studies are needed to clarify these findings.Publication Metadata only Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer(2023-03-01) YAŞAR, ALPER; BAYOĞLU, İBRAHİM VEDAT; KAHRAMAN S., ERUL E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., Acar O., AKSOY S., Baytemur N. K., ŞAHİN E., et al.Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.Publication Open Access Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy(2023-02-10) BAYOĞLU, İBRAHİM VEDAT; Karacin C., Oksuzoglu B., Demirci A., KESKİNKILIÇ M., Baytemür N. K., Yılmaz F., Selvi O., Erdem D., Avşar E., Paksoy N., et al.© 2023. The Author(s).BACKGROUND: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). METHODS: A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ≥ 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. RESULTS: The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0-14.0) months in the ET arm of group A, and 5.3 (3.9-6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8-7.7) months in the ET arm of group B, and 5.7 (4.6-6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5-8.0) months in the ET arm of group C and 4.0 (3.5-4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. CONCLUSION: Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET.Publication Open Access Prognostic significance of mucinous histology in metastatic colorectal cancer patients treated with regorafenib(2023-01-01) ARIKAN, RUKİYE; DEMİRCAN, NAZIM CAN; YAŞAR, ALPER; SEVER, NADİYE; ÇELİKEL, ÇİĞDEM; SARI, MURAT; KÖSTEK, OSMAN; BAYOĞLU, İBRAHİM VEDAT; ARIKAN R., Üstün H. S., Demircan N. C., Işik S., Telli T. A., Yaşar A., Çelebi A., Majidova N., Sever N., ÇELİKEL Ç., et al.Objective: Prognostic factors for regorafenib therapy have not been fully defined. Mucinous adenocarcinoma (MAC) is a dis-tinct subtype of colorectal cancer (CRC). We investigated the significance of mucinous histology in patients treated with regorafenib for metastatic CRC (mCRC). Material and Methods: In this retrospective study, patients were stratified according to the presence of mucinous histology; >1% extracellular mucin was defined as mucinous component adenocarcinoma (MCAC), and containing no mucin was defined as non-MAC. The prognostic significance of mucinous histology for progression-free survival (PFS) and overall survival (OS) was evaluated by univariate and multivariate analyses. Results: A total of 103 patients were included, including 20 (19.4%) patients with MCAC and 83 (80.6%) patients with non-MAC. The median follow-up time was 8.6 months (range 1.8-31.6 months). The median PFS was lower in cases with MCAC than those with non-MAC (3.2 months vs. 3.6 months, respectively, p=0.01). Median OS was lower in MCAC patients than in non-MAC patients (4.3 months vs. 9.6 months, respectively, p=0.008). In multivariate analyses, mucinous histology was an independent risk factor [haz-ard ratio (HR): 2.2, p=0.003] for PFS and Eastern Cooperative Oncology Group-Performance Status (HR: 2.2, p=0.01), cancer antigen 19-9 (HR: 1.7, p=0.03), and mucinous histology (HR: 1.9, p=0.02) were independent risk factors for OS. Conclusion: This study revealed the prognostic value of mucinous histology in mCRC patients treated with regorafenib. Consideration of histologic features may be helpful in se-lecting patients for regorafenib therapy.Publication Open Access Varicella-zoster virus infection and brivudine therapy: unexpected response in sarcoma patient(2022-01-01) BAYOĞLU, İBRAHİM VEDAT; KÖSTEK, OSMAN; KÖSTEK O., Sari M., BAYOĞLU İ. V.Soft tissue sarcoma is a heterogeneous disease and treatment options are limited in advanced stage settings. Brivudine is a thymidine-nucleoside analog and inhibits DNA polymerase in VZV infection. We demonstrated a case of a patient who was diagnosed with both VZV infection and advanced stage sarcoma, and unexpected anti-tumoral response after brivudine therapy.Publication Metadata only Prognostic Factors Associated with Resected Osteosarcoma: Efficacy of Adjuvant Setting, Real-World Experience(2024-01-01) ŞİMŞEK, FATİH; SEVER, NADİYE; KOCAASLAN, ERKAM; EREL, PINAR; ARIKAN, RUKİYE; SARI, MURAT; BAYOĞLU, İBRAHİM VEDAT; KÖSTEK, OSMAN; Majidova N., ŞİMŞEK F., Biter S., YASLIKAYA Ş., Seyyar M., DUYGULU M. E., Arcagok M., Kircali M. F., Sever N., KOCAASLAN E., et al.Osteosarcoma is a curable tumor. Surgery is performed after neoadjuvant chemotherapy as the primary standard treatment, followed by adjuvant therapy again. However, it is seen in patients who have undergone surgery without neoadjuvant chemotherapy. Adjuvant treatment is always given in this group. However, it is controversial how many cycles of adjuvant treatment should be given. In our study, 42 patients with osteosarcoma who received only adjuvant treatment without neoadjuvant treatment were analyzed for the effects of epidemiologic factors, treatment regimens on overall survival and disease-free survival. Retrospectively, 42 osteosarcoma patients (5 centers) with a current age of 18years and older who were followed up between 2001-2022 were examined. Twenty-five (60.0%) were below 8 cm, and 16 (38.0%) were 8 cm and above. The median number of cycles of adjuvant chemotherapy was 4 (range; 1-6). The 4-year DFS rate was 50.2%. In patients with primary tumors smaller and larger than 8cm, the 4-year DFS rates were 66.1% and 22.2%, respectively. The 4-year DFS rates for patients with 4 or less and more than 4 cycles of adjuvant chemotherapy were 27.1% and 69.2%, respectively. The 4-year OS rate was 78.5% in patients with primary tumors smaller than 8 cm and 18.8% in patients with tumors larger than 8 cm. The 4-year OS rate was 24.3% in patients who received 4 or less adjuvant cycles and 79.5% in patients who received more than 4 cycles. We have demonstrated that the number of adjuvant therapy courses above 4 and the presence of primary tumors smaller than 8 cm are influential over overall and disease-free survival in the patients who did not receive neoadjuvant therapy. The number of postoperative adjuvant treatment cycles should be forced as much as possible in these patients who haven’t had neoadjuvant therapy.Publication Open Access Impact of skeletal muscle measurements by chest computed tomography on survival and postoperative complications in patients with soft tissue sarcoma(2022-01-01) ARIKAN, RUKİYE; EROL, BÜLENT; KÖSTEK, OSMAN; BAYOĞLU, İBRAHİM VEDAT; DANE, FAYSAL; YUMUK, PERRAN FULDEN; ÖZGEN, ZERRİN; BUĞDAYCI, ONUR; AKIN TELLİ T., BUĞDAYCI O., Alan O., Sariyar N., Isik S., Arikan R., Yasar A., Majidova N., Celebi A., EROL B., et al.© 2022 Taylor & Francis Group, LLC.This study aims to evaluate whether sarcopenia, measured by chest computed tomography (CT), affects survival outcomes and postoperative complications in soft tissue sarcoma (STS) patients undergoing surgery. In this retrospective study, CT scans of 79 patients were reviewed to measure pectoralis and T12 vertebra muscle area. Both were then adjusted for height (cm2/m2) as pectoralis muscle index (PMI) and T12 vertebra muscle index (TMI). Analyses were performed by dichotomizing muscle indices at gender-specific 50th percentile; PMI and TMI < 50th percentile were defined as low, and ≥50th percentile as high. Overall postsurgical complication rate (PCR) was 16%. Median length of hospital stay (LOHS) was 10 days (3–90). PMI and TMI were significantly lower in women (p = 0.02, p = 0.04). Median body mass index was significantly higher in high PMI and TMI groups (p = 0.01 for both). PCR and LOHS were similar between low and high PMI and TMI groups. Median follow-up was 29 months, 37 patients had recurrence and 23 died. No significant difference was noted between low and high PMI and TMI groups, in terms of disease-free or overall survival. PMI and TMI as measured by chest CT had no impact on survival outcomes or postoperative complications in localized STS.